Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BRIEF-Pharmena Plans To Launch Sales Of 1-MNA Dietary Supplements In Poland, Europe

Published 26/09/2018, 05:22 pm
Updated 26/09/2018, 05:30 pm
© Reuters.  BRIEF-Pharmena Plans To Launch Sales Of 1-MNA Dietary Supplements In Poland, Europe

Sept 26 (Reuters) - PHARMENA SA PHR.WA :

* PRESENTS ITS STRATEGY TO LAUNCH SALES OF 1-MNA DIET SUPPLEMENTS IN POLAND AND EUROPE

* UNDER STRATEGY PLANS TO BUILD BRAND TO SELL SUPPLEMENTS, PHARMACIES TO BE MAIN DISTRIBUTION SOURCE IN POLAND

* SAYS IN 2019-2023 PLANS TO ESTABLISH AT LEAST THREE UNITS RESPONSIBLE FOR SALES IN SPECIFIC COUNTRY OR PART OF EUROPE

* ESTIMATES COSTS OF STRATEGY IMPLEMENTATION IN POLAND, EUROPE AT SEVERAL MILLION ZLOTYS

* PLANS TO FINANCE STRATEGY THROUGH SERIES E SHARE ISSUE

* SAYS HAS ANALYSED POSSIBILITY TO INTRODUCE 1-MNA DIETARY SUPPLEMENTS ON MARKETS OF CHINA, JAPAN, INDIA AND AUSTRALIA

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.